GlassScriptPhysician profile
Wendell C John
NPI 1942288790
$1,181.11
in general payments reported to CMS, 2019-2025
15 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.12 · 2023: $311 · 2024: $396 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.18 | 2022-2025 | |
| Lilly USA, LLC | $349.80 | 2022-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $71.95 | 2024-2025 | Rexulti |
| Abbott Laboratories | $67.28 | 2023-2024 | Proclaim, Octrode |
| Gilead Sciences, INC. | $52.85 | 2024 | |
| Axsome Therapeutics, INC. | $45.97 | 2025 | Auvelity |
| Exact Sciences Corporation | $32.08 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $25.61 | 2023 | Intellis Adaptivestim |
| Hologic Sales and Service, LLC | $20.08 | 2025 | Aptima |
| Janssen Pharmaceuticals, INC | $19.47 | 2025 | Spravato |
| Novo Nordisk INC | $16.44 | 2025 | Wegovy |
| Phadia US INC. | $14.85 | 2023 | Immunocap |
| Avion Pharmaceuticals | $14.23 | 2023 | Balcoltra |
| Astrazeneca Pharmaceuticals LP | $13.80 | 2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $13.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.